Trials / Completed
CompletedNCT00097942
Evaluation of the Safety and Efficacy of Memantine as Adjunctive Treatment in Schizophrenia Patients
A Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Memantine as Adjunctive Treatment to Atypical Antipsychotics in Schizophrenia Patients With Persistent Residual Symptoms
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 138 (actual)
- Sponsor
- Forest Laboratories · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Standard antipsychotic drug regimens do not fully address the impact of cognitive symptoms associated with schizophrenia. The NMDA receptor has been connected to the pathophysiology of schizophrenia. Memantine is an uncompetitive NMDA receptor antagonist. It is hypothesized that adjunctive therapy with memantine will reduce NMDA receptor hyperactivity, improving signal to noise ratio and thereby improving cognitive symptoms.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | memantine HCl |
Timeline
- Start date
- 2004-08-01
- Primary completion
- 2005-09-01
- Completion
- 2005-09-01
- First posted
- 2004-12-02
- Last updated
- 2012-03-05
Locations
13 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00097942. Inclusion in this directory is not an endorsement.